Evidence map›Paper›PMID 27687248›Full record

ArticleBreast cancer research : BCR2016

Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells.

Matthias Ilmer, Nachman Mazurek, Michael Z Gilcrease, James C Byrd, Wendy A Woodward, Thomas A Buchholz, Kim Acklin, Karen Ramirez, Margarete Hafley, Eckhard Alt and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research : BCR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Galectins as Molecular Targets for Therapeutic Intervention.International journal of molecular sciences · 2018
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Matthias IlmerCurrent address: Department of General, Visceral and Transplantation Surgery, Hospital of the University of Munich (LMU), Munich, Germany.ORCID 0000-0001-9597-1368
Nachman MazurekDepartment of Gastroenterology, Hepatology and Nutrition, MD Anderson Cancer Center (MDACC), University of Texas Health Science Center at Houston, Houston, TX, USA.
Michael Z GilcreaseDepartment of Pathology, MD Anderson Cancer Center (MDACC), University of Texas Health Science Center at Houston, Houston, TX, USA.
James C ByrdDepartment of Gastroenterology, Hepatology and Nutrition, MD Anderson Cancer Center (MDACC), University of Texas Health Science Center at Houston, Houston, TX, USA.
Wendy A WoodwardDepartment of Breast Radiation Oncology, MD Anderson Cancer Center (MDACC), University of Texas Health Science Center at Houston, Houston, TX, USA.
Thomas A BuchholzDepartment of Breast Radiation Oncology, MD Anderson Cancer Center (MDACC), University of Texas Health Science Center at Houston, Houston, TX, USA.
Kim AcklinDepartment of Stem Cell Transplantation and Cellular Therapies, MD Anderson Cancer Center (MDACC), University of Texas Health Science Center at Houston, Houston, TX, USA.
Karen RamirezDepartment of Stem Cell Transplantation and Cellular Therapies, MD Anderson Cancer Center (MDACC), University of Texas Health Science Center at Houston, Houston, TX, USA.
Margarete HafleyDepartment of Gastroenterology, Hepatology and Nutrition, MD Anderson Cancer Center (MDACC), University of Texas Health Science Center at Houston, Houston, TX, USA.
Eckhard AltDepartment of Medicine, Tulane University Health Science Center, New Orleans, LA, USA.
Jody VykoukalDepartment of Translational Molecular Pathology, MD Anderson Cancer Center (MDACC), University of Texas Health Science Center at Houston, Houston, TX, USA.
Robert S BresalierDepartment of Gastroenterology, Hepatology and Nutrition, MD Anderson Cancer Center (MDACC), University of Texas Health Science Center at Houston, Houston, TX, USA. rbresali@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USLMU Klinikum · DETulane University · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
MUCIN GLYCOPROTEINS IN COLON CANCER METASTASISR01CA069480 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BRESALIER, ROBERT S · 1996 to 2010
$2.6M
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA069480
6 · The paper itself

Abstract

backgroundGalectin-3 (Gal3) plays diverse roles in cancer initiation, progression, and drug resistance depending on tumor type characteristics that are also associated with cancer stem cells (CSCs). Recurrence of breast carcinomas may be attributed to the presence of breast CSCs (BCSCs). BCSCs exist in mesenchymal-like or epithelial-like states and the transition between these states endows BCSCs with the capacity for tumor progression. The discovery of a feedback loop with galectins during epithelial-to-mesenchymal transition (EMT) prompted us to investigate its role in breast cancer stemness.

methodTo elucidate the role of Gal3 in BCSCs, we performed various in vitro and in vivo studies such as sphere-formation assays, Western blotting, flow cytometric apoptosis assays, and limited dilution xenotransplant models. Histological staining for Gal3 in tissue microarrays of breast cancer patients was performed to analyze the relationship of clinical outcome and Gal3 expression.

resultsHere, we show in a cohort of 87 node-positive breast cancer patients treated with doxorubicin-based chemotherapy that low Gal3 was associated with increased lymphovascular invasion and reduced overall survival. Analysis of in vitro BCSC models demonstrated that Gal3 knockdown by small hairpin RNA (shRNA) interference in epithelial-like mammary spheres leads to EMT, increased sphere-formation ability, drug-resistance, and heightened aldefluor activity. Furthermore, Gal3

conclusionsThus, in at least some breast cancers, loss of Gal3 might be associated with EMT and cancer stemness-associated traits, predicts poor response to chemotherapy, and poor prognosis.

Indexed as

Gene ExpressionAdultAgedAged, 80 and overAnimalsBiomarkers, TumorBreast NeoplasmsCell Line, TumorDisease Models, AnimalFemaleGalectin 3Gene Knockdown TechniquesHeterograftsHumansLymphatic MetastasisMiceBiomarkers, TumorGalectin 3Proto-Oncogene Proteins c-aktBreast cancerCancer stem cells (CSC)Epithelial-mesenchymal transition (EMT)Galectin-3 (Gal3)

Identifiers

PMID27687248
PMCPMC5043623
OpenAlexW2527610870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.